DocGo Inc. Segment Expenditure Addition To Long Lived Assets
DocGo Inc. (DCGO) reported Segment Expenditure Addition To Long Lived Assets of $1.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2026-08-17
- DocGo Inc. segment expenditure addition to long lived assets for the quarter ending 2026-06-30 was $1.82M, a 42.49% decline year-over-year.
- DocGo Inc. segment expenditure addition to long lived assets for the quarter ending 2026-03-31 was $2.95M, a 70.31% decline year-over-year.
- DocGo Inc. segment expenditure addition to long lived assets for the quarter ending 2025-12-31 was $8.67M, a 664.56% increase year-over-year.
- DocGo Inc. segment expenditure addition to long lived assets for the quarter ending 2025-09-30 was $2.86M, a 32.47% decline year-over-year.
- DocGo Inc. segment expenditure addition to long lived assets for fiscal 2025 was $24.61M, a 71.89% increase from fiscal 2024.
- DocGo Inc. segment expenditure addition to long lived assets for fiscal 2024 was $14.32M, a 71.93% decline from fiscal 2023.
- DocGo Inc. segment expenditure addition to long lived assets for fiscal 2023 was $51.02M, a 45.85% decline from fiscal 2022.
- DocGo Inc. segment expenditure addition to long lived assets for fiscal 2022 was $94.22M.
| Period end | Segment Expenditure Addition To Long Lived Assets 3 month | Segment Expenditure Addition To Long Lived Assets 6 month | Segment Expenditure Addition To Long Lived Assets 9 month | Segment Expenditure Addition To Long Lived Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.82M 10-Q · filed 2026-08-17 | $4.77M 10-Q · filed 2026-08-17 | $13.43M derived: sum of 3 quarters · filed 2026-08-17 | $16.29M derived: sum of 4 quarters · filed 2026-08-17 |
| 2026-03-31 | $2.95M 10-Q · filed 2026-05-11 | $11.61M derived: sum of 2 quarters · filed 2026-05-11 | $14.47M derived: sum of 3 quarters · filed 2026-05-11 | $17.63M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-12-31 | $8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $11.52M derived: sum of 2 quarters · filed 2026-03-16 | $14.68M derived: sum of 3 quarters · filed 2026-08-17 | $24.61M 10-K · filed 2026-03-16 |
| 2025-09-30 | $2.86M 10-Q · filed 2025-11-10 | $6.02M derived: sum of 2 quarters · filed 2026-08-17 | $15.95M 10-Q · filed 2025-11-10 | $17.08M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-06-30 | $3.16M 10-Q · filed 2026-08-17 | $13.09M 10-Q · filed 2026-08-17 | $14.22M derived: sum of 3 quarters · filed 2026-08-17 | $18.45M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-03-31 | $9.93M 10-Q · filed 2026-05-11 | $11.06M derived: sum of 2 quarters · filed 2026-05-11 | $15.29M derived: sum of 3 quarters · filed 2026-05-11 | $20.11M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.36M derived: sum of 2 quarters · filed 2026-03-16 | $10.18M derived: sum of 3 quarters · filed 2026-03-16 | $14.32M 10-K · filed 2026-03-16 |
| 2024-09-30 | $4.23M 10-Q · filed 2025-11-10 | $9.05M derived: sum of 2 quarters · filed 2025-11-10 | $13.19M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $4.82M 10-Q · filed 2025-08-07 | $8.95M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $4.14M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $51.02M 10-K · filed 2026-03-16 | |||
| 2022-12-31 | $94.22M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |